shutterstock_1492661771_ricochet64-1

ricochet64 / Shutterstock.com

14 July 2022Big PharmaMuireann Bolger

Generic drug maker fails to avoid inhaler patent lawsuit

A Virginia court was unconvinced that the Hatch-Waxman Act did not apply.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27 January 2022 AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

More on this story

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27 January 2022 AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

More on this story

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27 January 2022 AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?